Deep Dive: Shared Dairy Supply Chain Links Two Infant Botulism Outbreaks — Background, What Changed, Competing Viewpoints, and What to Watch

Shared Dairy Supply Chain Links Two Infant Botulism Outbreaks

Background

Infant botulism is rare but serious. It occurs when spores of Clostridium botulinum colonize an infant’s immature gut and produce toxin. Until 2025, no outbreak had been linked to powdered infant formula anywhere in the world.

In late 2025, ByHeart Whole Nutrition powdered infant formula was linked to 48 hospitalizations across 17 states (onsets December 2023–November 2025). CDC declared that outbreak over in February 2026. Then in spring 2026, four more infants in California, Pennsylvania, and Washington were hospitalized after consuming Nara Organics Whole Milk Organic powdered formula. CDC declared the Nara outbreak over on 27 August 2026.

What changed

Whole-genome sequencing showed a genetic match between a clinical sample from the Nara outbreak, samples from the ByHeart outbreak, unopened ByHeart cans, and base powder. Both products used milk supplied by Organic West Milk and spray-dried by Dairy Farmers of America in Fallon, Nevada.

FDA’s root-cause investigation continues. Plant environmental samples at ByHeart were negative; the organism was found in the dairy ingredient. A February 2026 surveillance sampling of 48 powdered-milk samples from four suppliers found two positives by PCR (organic nonfat milk powder). FDA has written the industry three letters since March 2023 naming C. botulinum as a hazard to consider. It has not yet added the organism to the mandatory finished-product testing list under 21 CFR § 106.55.

On 15 October 2026, food-safety attorney Bill Marler released a draft citizen petition (comments due 30 October) asking FDA to require testing of powdered infant formula and dairy ingredients for botulinum neurotoxin-producing clostridia. The petition is supported by parents of 23 hospitalized infants.

Competing viewpoints

Parents and public-health advocates argue that voluntary industry testing has proven insufficient for a sole-source infant food, pointing to the shared-supplier link and the fact that Cronobacter was added to the testing list in 2014 on a much smaller case load. They note that current methods are slow (weeks for confirmation) and that an interim method presented in July 2026 is still pending validation.

Industry and some regulators note that spores are ubiquitous in the environment, that testing finished product for a rare spore-former has sensitivity and cost challenges, and that the root cause (pre-drying contamination vs. process) is not yet settled. FDA has focused on supplier oversight letters rather than an immediate rule, while supporting international risk assessments (JEMRA, ICMSF).

What to watch

• The comment period on the Marler petition closes 30 October 2026.
• FDA’s ongoing root-cause work and any updates to surveillance sampling.
• Whether the agency moves from letters to a proposed rule adding C. botulinum to the testing list.
• Clinic practice: any infant with constipation, weak suck, or floppy appearance who consumed powdered formula should prompt immediate consultation with the California Infant Botulism Treatment and Prevention Program (510-231-7600). Treatment with BabyBIG should not wait for lab confirmation.

This is editorial context for parents, not medical or legal advice. Check lot numbers of any remaining powdered formula and follow official recall notices.

Sources: FDA post-outbreak response pages, CDC outbreak summaries, Contemporary Pediatrics reporting, Marler Blog draft petition (15 Oct 2026).